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Abstract
Introduction Certain lipids have been shown to be ligands for a
subgroup of the nuclear hormone receptor superfamily known
as the peroxisome proliferator-activated receptors (PPARs).
Ligands for these transcription factors have been used in
experimental cancer therapies. PPARs heterodimerize and bind
DNA with retinoid X receptors (RXRs), which have homology to
other members of the nuclear receptor superfamily. Retinoids
have been found to be effective in treating many types of cancer.
However, many breast cancers become resistant to the
chemotherapeutic effects of these drugs. Recently, RXR-
selective ligands were discovered that inhibited proliferation of
all-trans retinoic acid resistant breast cancer cells in vitro and
caused regression of the disease in animal models. There are
few published studies on the efficacy of combined therapy using
PPAR and RXR ligands for breast cancer prevention or
treatment.
Methods We determined the effects of selective PPAR and
RXR ligands on established human breast cancer cell lines in
vitro.
Results PPAR-α and PPAR-γ ligands induced apoptotic and
antiproliferative responses in human breast cancer cell lines,
respectively, which were associated with specific changes in
gene expression. These responses were potentiated by the
RXR-selective ligand AGN194204. Interestingly, RXR-α-
overexpressing retinoic acid resistant breast cancer cell lines
were more sensitive to the effects of the RXR-selective
compound.
Conclusion RXR-selective retinoids can potentiate the
antiproliferative and apoptotic responses of breast cancer cell
lines to PPAR ligands.
Keywords: cell cycle, chemotherapy, hormones, nuclear receptors, transcription factors
Introduction
Within the past few years, specific lipids have been shown
to be ligands for a subgroup of the nuclear hormone recep-
tor superfamily known as the peroxisome proliferator-acti-
vated receptors (PPARs; for review, see Mandrup and Lane
[1]). The first of these ligand-dependent transcription fac-
tors, namely PPAR-α, was originally cloned as an orphan
receptor that was activated by agents that induce peroxi-
some proliferation in the liver (for review, see Keller and
Wahli [2]). Subsequently, PPAR-δ (also known as PPAR-β)
and PPAR-γ were cloned by low stringency screening [3].
Like other members of the nuclear receptor superfamily,
PPARs have functional domains for DNA and ligand bind-
ing [4]. PPARs bind to recognition sequences in the pro-
moter regions of their target genes to regulate
transcription. These sequences typically contain a direct
repeat of the motif PuGGTCA separated by one nucle-
otide; this sequence is recognized by other members of the
nuclear hormone receptor superfamily, such as retinoid X
receptors (RXRs) [5]. These receptors exhibit markedly dif-
ferent tissue distributions, DNA binding affinities, and lig-
and preferences. PPARs are activated by long-chain fatty
acids (for review, see Kliewer and coworkers [6]). PPAR-α
can be selectively activated by hydroxyeicosatetraenoic
BrdU = bromodeoxyuridine; Cdk = cyclin-dependent kinase; ERK = extracellular signal-regulated kinase; HETE = hydroxyeicosatetraenoic acid; LA 
= γ-linolenic acid; PBS = phosphate-buffered saline; PPAR = peroxisome proliferator-activated receptor; RA = retinoic acid; RAR = retinoic acid 
receptor; RXR = retinoid X receptor; TUNEL = dUTP nick-end labeling; TZD = thiazolidinedione drug.Breast Cancer Research    Vol 6 No 5    Crowe and Chandraratna 
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acid (HETE) and fibrates, whereas PPAR-γ preferentially
binds  γ-linolenic acid (LA), prostaglandin J2 metabolites,
and thiazolidinedione drugs (TZDs) [6,7].
Given the ability of PPARs to induce differentiation of a vari-
ety of cell types, ligands for these transcription factors have
been used in experimental cancer therapies (for review, see
Roberts-Thomson [8]). TZD administration to liposarcoma
patients induced histologic and biochemical differentiation
markers in vivo [9]. TZD treatment of human bladder carci-
noma cells in vitro inhibited cellular proliferation via
increased cyclin-dependent kinase (Cdk) inhibitor expres-
sion and induced cell death [10]. Similarly, the growth of
human lung cancer cell lines was inhibited via apoptosis
when cultures were treated with TZDs but not the PPAR-γ
agonist bezafibrate [11]. TZDs also induced differentiation
of human colon cancer cell lines in vitro with concomitant
growth arrest [12]. Loss of function mutations in PPARs
that impaired ligand binding have also been found in colon
cancer [13]. Human breast cancer cell lines express
PPARs [14], and fatty acids were able to stimulate activa-
tion of a reporter gene via PPAR-γ [15,16]. As seen in other
cancers, TZDs induced growth arrest and differentiation in
breast carcinoma cells in vitro and in animal models
[17,18]. However, a small phase II study of the PPAR-γ lig-
and troglitazone failed to identify objective responses in
patients with refractory breast cancer [19].
PPARs heterodimerize and bind DNA with RXRs, which
have homology to other members of the nuclear receptor
superfamily (for review, see Mangelsdorf and Evans [20]).
The natural ligand for RXRs is 9-cis retinoic acid (RA) [21].
RXR heterodimers typically bind to the 5' half of the DNA
direct repeat and may also homodimerize [22]. However, in
PPAR/RXR heterodimers, the retinoid receptor occupies
the 3' half of the response element [5]. Heterodimerization
greatly enhances DNA binding and transcriptional activa-
tion [23,24]. RXR overexpression has been reported to
enhance the transcriptional response to ligand binding
[25].
Retinoids have been effective in vitro against many types of
cancer, including that of the breast [26-30]. However,
many breast cancers become resistant to the chemothera-
peutic effects of these drugs [31-33]. Recently, RXR-selec-
tive ligands were discovered that inhibited proliferation of
all-trans RA resistant breast cancer cells in vitro and
caused regression of the disease in animal models [34].
These RXR-selective ligands did not produce the side
effects that are normally associated with retinoid chemo-
therapy [35]. However, a phase II trial using one of these
ligands (bexarotene) showed limited response in patients
with metastatic breast cancer [36]. Interestingly, a high-risk
lesion for invasive breast cancer, ductal carcinoma in situ,
has been shown to overexpress RXR-α [37].
The effects of PPAR and RXR ligands on established
breast cancer cell lines require further study. The evaluation
of new RXR ligands that cooperate with PPARs may result
in important therapeutic breakthroughs. To provide a
molecular and cell biologic basis for these studies, we
examined the effects of selective PPAR and RXR ligands
on established breast cancer cell lines in vitro. We deter-
mined that the RXR-selective ligand potentiated the anti-
proliferative and apoptotic responses to PPAR ligands in
human breast cancer cell lines. RA-resistant lines that over-
expressed RXR-α were more sensitive to the effects of
these ligands, suggesting potential therapeutic uses for
these compounds.
Methods
Cell culture and stable transfection
The human breast cancer cell lines used in the present
study were purchased from the American Type Culture
Collection. Cells were cultured in Dulbecco's modified
Eagle's medium, 10% fetal bovine serum, and 40 µg/ml
gentamicin at 37°C in a humidified atmosphere of 5% car-
bon dioxide. T47D cells were transfected with 5 µg expres-
sion vector for RXR-α (kindly provided by Dr Ronald Evans)
or neomycin resistance plasmid alone using Lipofectamine
reagent (Invitrogen, Carlsbad, CA, USA), in accordance
with the manufacturer's recommendations. Cells were
selected in 400 µg/ml G418 for 14 days. Resistant clones
were picked for expansion and characterization. RXR-α
expression was determined by western blot (see below).
Cell death and proliferation assays
The dUTP nick-end labeling (TUNEL) assay for in situ cell
death detection was performed using a commercially avail-
able kit (Roche Molecular Biochemicals, Indianapolis, IN,
USA). Cells were treated with 0.1% dimethyl sulfoxide vehi-
cle, 100 µmol/l HETE, 100 µmol/l LA, or 100 nmol/l of the
RXR-selective retinoid AGN194204. Cells were fixed in
4% paraformaldehyde (pH 7.4) and permeabilized with
0.1% Triton X-100, 0.1% sodium citrate for 2 min on ice. A
mouse IgM anti-human Fas antibody (Molecular Biology
Laboratories, Woburn, MA, USA) that induces apoptosis in
sensitive cell lines was used as the positive control. An iso-
type matched control antibody was used as the negative
control. After washing with phosphate-buffered saline
(PBS), cells were incubated with fluorescein-dUTP and ter-
minal deoxynucleotidyl transferase for 60 min at 37°C, in
accordance with the manufacturer's recommendations
(Roche Molecular Biochemicals). After washing three times
in PBS, apoptotic cells were visualized by fluorescence
microscopy. Proliferation was analyzed by plating 5 × 104
cells in triplicate cultures and treating with vehicle, PPAR,
or RXR selective ligands for up to 6 days. Cells were
trypsinized and counted with a hemacytometer at 2-day
intervals.Available online http://breast-cancer-research.com/content/6/5/R546
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To determine G1 to S phase progression, bromodeoxyurid-
ine (BrdU) incorporation analysis was performed. Vehicle
and ligand treated cells were incubated with 10 µmol/l
BrdU for 1 hour, washed in PBS, and fixed in 70% ethanol
containing 50 mmol/l glycine (pH 2) for 20 min at -20°C.
After washing in PBS, the cells were incubated with mouse
anti-BrdU primary antibody for 30 min at 37°C, in accord-
ance with the manufacturer's recommendations (Roche
Molecular Biochemicals). The cells were washed in PBS
and incubated with anti-mouse IgG secondary antibody
conjugated to fluorescein. Following extensive washing in
PBS, the number of BrdU-positive cells were visualized by
fluorescence microscopy and expressed as a percentage
of the total cells counted in 10 random high-power fields.
Western blot
Total protein (75 µg) from vehicle or ligand treated cells
was separated by SDS-PAGE on 10% resolving gels
under denaturing and reducing conditions. Separated pro-
teins were electroblotted to polyvinylidene difluoride mem-
branes, in accordance with the manufacturer's
recommendations (Bio-Rad, Hercules, CA, USA). Blots
were incubated with anti-human primary antibodies to
PPARs, retinoic acid receptors (RARs), RXRs, cyclins,
Cdks, epidermal growth factor receptor, c-met, extracellu-
lar signal-regulated kinases (ERKs), p38, c-myc, AP-1 pro-
teins, caspases, and β-actin (Transduction Laboratories,
San Diego, CA, USA and Santa Cruz Biotechnology, Santa
Cruz, CA, USA) for 16 hours at 4°C. After washing in Tris-
buffered saline containing 0.1% Tween 20 (pH 7.5), blots
were incubated for 30 min at room temperature with anti-
IgG secondary antibody conjugated to horseradish peroxi-
dase. After extensive washing in Tris-buffered saline con-
taining 0.1% Tween 20 at room temperature, bands were
visualized by the enhanced chemiluminescence method
(Roche Molecular Biochemicals).
Immunoprecipitation
Cells were lysed in 50 mmol/l HEPES (pH 7.5), 150 mmol/
l NaCl, 1 mmol/l EDTA, 2.5 mmol/l EGTA, 1 mmol/l DTT,
1% Nonidet P-40, 10% glycerol, and protease inhibitors for
30 min at 4°C. Lysates were centrifuged at 10,000 g for 10
min and anti-human primary antibody to RXR-α (Santa Cruz
Biotechnology) was incubated with the supernatants for 1
hour at 4°C. Antigen–antibody complexes were precipi-
tated by incubation with protein A/G agarose (Santa Cruz
Biotechnology) for 1 hour at 4°C. Immunoprecipitated pro-
teins were washed three times with 1 ml lysis buffer. Immu-
noprecipitated protein complexes were separated by SDS-
PAGE as described above. Blots were incubated with anti-
PPAR antibodies for 16 hours at 4°C. Blots were stripped
and incubated with anti-RXR-α antibody to determine
amounts of immunoprecipitated protein in each lane.
Transient transfection and reporter gene assays
Human breast cancer cell lines were plated in triplicate into
six-well tissue culture plates. Cells were transiently trans-
fected with 5 µg of a heterologous promoter containing a
direct repeat of the PPAR recognition sequence (5'-AGGT-
CAGAGGTCA-3') cloned in the pGL3 luciferase reporter
vector (Promega, Madison, WI, USA) using Lipofectamine
(Invitrogen), in accordance with the manufacturer's recom-
mendations. β-Galactosidase expression vector 1 µg was
used to normalize for transfection efficiency. Cells were
treated with vehicle, 100 µmol/l LA, 100 nmol/l all-trans
RA, 100 nmol/l AGN194204, or a combination of LA plus
RA or LA plus AGN194204 for 24 hours following trans-
fection. Reporter gene activity was determined using a
commercially available kit (Dual-light; Tropix, Foster City,
CA, USA). Luciferase activity was normalized to β-galac-
tosidase levels for each sample.
Results
Expression of functional PPAR and RXR proteins
To determine the expression of PPARs, RARs, and RXRs in
human breast cancer cells, we analyzed six lines by west-
ern blot. As shown in Fig. 1a, all human breast cancer cell
lines expressed low levels of PPAR-α. Expression of PPAR-
α was sixfold higher in Hs578T cells than in the other five
lines. Relative expression of PPAR-γ was considerably
higher than that of PPAR-α; however, PPAR-γ expression
was threefold lower in MCF7 and Hs578T cells than in
other lines. RAR-α protein was detected in all cell lines with
the exception of T47D, and expression was generally lower
in RA-resistant lines such as MDA-MB-231 and MDA-MB-
468. RAR-β expression was below the limit of detection for
western blot with the exception of the T47D and SKBR3
lines, in which low levels of the protein were detected.
RXR-α expression was low or undetectable in most lines,
but it was threefold higher in MDA-MB-468 and SKBR3
cells. We did not detect expression of other PPAR, RAR, or
RXR proteins in these cell lines. We concluded that PPARs
and RAR-α proteins were expressed in human breast can-
cer cell lines, with higher RXR-α levels in two out of four
estrogen receptor negative lines.
PPARs have been shown to heterodimerize with RXRs to
activate gene transcription [20]. To determine whether
PPAR-α and PPAR-γ could dimerize with RXR-α in human
breast cancer lines, we immunoprecipitated the retinoid
receptor from these cells. As shown in Fig. 1b, RXR-α pro-
tein could be detected by the more sensitive immunopre-
cipitation technique in all cell lines tested. To determine
whether PPARs associated with RXR-α in these lines, we
incubated these blots with anti-PPAR-α and PPAR-γ anti-
bodies. Both PPARs immunoprecipitated with RXR-α pro-
tein in all cell lines. These results indicate that PPARs and
RXR-α interact in human breast cancer cell lines.Breast Cancer Research    Vol 6 No 5    Crowe and Chandraratna 
R549
To determine whether these heterodimers could activate a
PPAR-responsive promoter, we transiently transfected four
breast cancer cell lines with a heterologous PPAR pro-
moter vector and determined reporter gene activity in
response to selective ligands. As shown in Fig. 1c, treat-
ment with 100 µmol/l LA (a selective PPAR-γ ligand)
resulted in threefold to fourfold induction of promoter activ-
ity in all cell lines. Treatment with 100 nmol/l of the RXR-
selective compound AGN194204 produced twofold to
threefold increases in promoter activity in these lines. How-
ever, treatment with the RAR agonist all-trans RA failed to
induce promoter activity, indicating the specificity of this
promoter construct. Treatment of transiently transfected
breast cancer cell lines with LA and RA simultaneously did
not induce activity above that observed with LA alone.
However, combining LA with AGN194204 resulted in an
eightfold induction of promoter activity in MCF7 and T47D
lines, and 15- to 17-fold induction in MDA-MB-468 and
SKBR3 cells, which express higher levels of RXR-α. These
results indicate that PPAR/RXR heterodimers are func-
tional in human breast cancer lines, and that RXR-selective
ligands can potentiate PPAR-induced transcriptional acti-
vation in cells with higher levels of RXR-α.
PPAR-γ/RXR synergy results in antiproliferative effects 
on human breast cancer cell lines
These findings suggest that the RXR-selective ligand
AGN194204 may be more biologically active against RXR-
α overexpressing breast cancer cell lines. To examine this
possibility, we evaluated the proliferative response of this
compound as a single agent or in combination with PPAR-
selective ligands. As shown in Fig. 2a, treatment with 100
nmol/l AGN194204 slightly inhibited proliferation of T47D
cells. The PPAR-γ selective ligand LA was a more effective
antiproliferative agent in vitro, producing 30% inhibition of
cell growth in these assays. Simultaneous treatment with
both ligands resulted in an additive effect, producing 40%
growth inhibition of T47D cells. In contrast, AGN194204
was a highly effective antiproliferative compound (70%
growth inhibition) when used as a single agent on MDA-
MB-468 cells, which express higher levels of RXR-α (Fig.
2b). Similar results were obtained using SKBR3 cells (data
not shown). LA treatment of MDA-MB-468 cells resulted in
20% growth inhibition when used as a single agent, but
because of the magnitude of the AGN194204 effect we
did not observe additional antiproliferative activity when
both ligands were used together.
To determine whether LA and AGN194204 inhibited S-
phase progression in human breast cancer cell lines, we
performed BrdU incorporation analysis. As shown in Fig.
2c, LA treatment reduced the number of BrdU positive cells
by 30–50%. AGN194204 had little effect on BrdU incor-
poration in T47D cells, but it inhibited S-phase progression
by 70% in the MDA-MB-468 line. These data indicate that
Figure 1
Expression of functionally interacting peroxisome proliferator-activated  receptors (PPARs), retinoic acid receptors (RARs), and retinoid X  receptors (RXRs) in human breast cancer cell lines Expression of functionally interacting peroxisome proliferator-activated 
receptors (PPARs), retinoic acid receptors (RARs), and retinoid X 
receptors (RXRs) in human breast cancer cell lines. (a) Whole cell 
lysates from the indicated breast cancer cell lines were subjected to 
western blot analysis using the anti-PPAR, anti-RAR, anti-RXR, and 
anti-β-actin antibodies shown on the left. Relative expression of each 
protein was determined using the same membrane. (b) Human RXR-α 
protein was immunoprecipitated (IP RXRα) from the indicated breast 
cancer cell lines. Immunoprecipitated complexes were subjected to 
western blotting using anti-PPAR-α and anti-PPAR-γ antibodies. Blots 
were stripped and incubated with anti-RXR-α antibody to determine the 
relative amounts of immunoprecipitated protein in each lane. These 
experiments were performed three times, with similar results. Repre-
sentative blots are shown. (c) An RXR-selective compound potentiates 
transcriptional activation by a PPAR ligand. The indicated human breast 
cancer cell lines were transiently transfected with a heterologous 
PPAR-responsive promoter/reporter construct and treated with 100 
µmol/l of the PPAR ligand γ-linolenic acid (LA), 100 nmol/l of the pan 
RAR agonist all-trans retinoic acid (RA), 100 nmol/l of the RXR-selec-
tive ligand AGN194204 (AGN), γ-linolenic acid and retinoic acid 
(LA+R), or γ-linolenic acid plus AGN194204 (LA+A) for 24 hours 
before determination of promoter activity. Promoter activity was repre-
sented as relative light units from the luciferase reporter. These experi-
ments were performed three times with similar results. Error bars 
indicate the standard error of the mean.Available online http://breast-cancer-research.com/content/6/5/R546
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Figure 2
Greater peroxisome proliferator-activated receptor (PPAR)-selective antiproliferative and apoptotic responses potentiated by AGN194204 in retin- oid X receptor (RXR)-α-overexpressing human breast cancer cell lines Greater peroxisome proliferator-activated receptor (PPAR)-selective antiproliferative and apoptotic responses potentiated by AGN194204 in retin-
oid X receptor (RXR)-α-overexpressing human breast cancer cell lines. (a) Triplicate cultures of estrogen receptor positive/retinoic acid (RA)-sensi-
tive T47D cells were treated for 6 days with vehicle (con), 100 µmol/l of the PPAR-γ ligand γ-linolenic acid (LA), 100 nmol/l AGN194204 (AGN), or 
both compounds simultaneously (LA+AGN). Proliferation was monitored by cell counting at 2-day intervals using a hemacytometer. (b) Triplicate 
cultures of estrogen receptor negative/RA-resistant MDA-MB-468 cells were treated for 6 days with vehicle (con), 100 µmol/l LA, 100 nmol/l 
AGN194204, or both compounds simultaneously (LA+AGN). Proliferation was monitored by cell counting at 2-day intervals using a hemacytometer. 
(c) LA and AGN194204 inhibit S-phase progression in human breast cancer cell lines. The indicated cell lines were treated with 100 µmol/l LA or 
100 nmol/l AGN194204 (AGN). The percentage of S-phase cells was determined by bromodeoxyuridine (BrdU) incorporation assay. (d) PPAR- 
and RXR-selective ligands alter expression of nonoverlapping sets of cell cycle regulatory proteins. Whole cell lysates from the indicated human 
breast cancer cell lines treated with 100 µmol/l LA for up to 24 hours were subjected to western blot with the antibodies shown on the left. Relative 
expression of each protein was determined using the same membrane. (e) Whole cell lysates from the indicated human breast cancer cell lines 
treated with 100 nmol/l AGN194204 for up to 24 hours were subjected to western blot with the antibodies shown on the left. Relative expression of 
each protein was determined using the same membrane.Breast Cancer Research    Vol 6 No 5    Crowe and Chandraratna 
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the RXR-selective ligand has substantial antiproliferative
activity in vitro against breast cancer cell lines expressing
higher levels of RXR-α.
To determine changes in expression of genes that regulate
cell cycle progression resulting from LA treatment of human
breast cancer cell lines, we examined protein levels by
western blot. As shown in Fig. 2d, most alterations in the
expression of these genes did not occur until 16 hours after
LA exposure. Cyclin E levels decreased by twofold at this
time point in T47D cells and was undetectable in the MDA-
MB-468 line. Cdk1 levels also decreased in both cell lines
by the 16-hour and 24-hour timepoints. By 24 hours, mark-
edly decreased protein levels of a number of cell cycle reg-
ulatory genes were noted, including ERK1, cyclin A, c-myc,
and JunB. The majority of these genes are involved in regu-
lating S-phase progression in many cell types. Regulation
of G2 phase proteins such as cyclin B were unaffected by
LA treatment (data not shown). These results indicate that
LA-induced changes in gene expression correlate with
delayed S-phase progression, as shown by BrdU incorpo-
ration analysis in human breast cancer cell lines.
Treatment with the RXR-selective ligand AGN194204
altered expression of a larger group of genes, including
those encoding growth factor receptors, mitogen-activated
protein kinases, cyclins, and Cdks. As shown in Fig. 2e,
expression of epidermal growth factor receptor and the
scatter factor receptor c-met, which are overexpressed in
MDA-MB-468 cells, was markedly inhibited by 16 hours of
exposure to AGN194204. Decreased expression of these
receptors in MDA-MB-468 cells correlated with reduced
levels of downstream signaling proteins in the mitogen-acti-
vated protein kinase pathway such as ERK1 and ERK3. In
contrast, levels of these proteins were largely unaffected in
T47D cells, which are less sensitive to the antiproliferative
effects of AGN194204. Cyclin B protein levels were also
decreased by 16 hours in the MDA-MB-468 line, but were
largely unaffected in T47D cells except for a transient
decrease observed at 8 hours. Expression of cyclin E,
Cdk1, Cdk6, and Fra-1 was inhibited by twofold to fourfold
in both cell lines by 8 hours; these genes represent the ear-
liest observed changes in response to AGN194204 in
these cell lines. In contrast, Cdk4 levels were largely unaf-
fected by AGN194204 in either cell line, indicating that the
observed changes in gene expression were specific. There-
fore, although some of the AGN194204-induced changes
in gene expression overlapped with those regulated by LA,
others were specific for each selective ligand. These data
indicate that increased sensitivity of RXR-α overexpressing
human breast cancer cell lines to AGN194204 is reflected
in changes in gene expression.
PPAR-α/RXR synergy results in apoptotic effects on 
human breast cancer cell lines
In contrast to the effects of LA, treatment of breast cancer
cell lines with 100 nmol/l of the PPAR-α selective ligand
HETE resulted in nuclear condensation, cell rounding, and
detachment from the culture dish, which is indicative of
apoptosis (data not shown). To confirm this interpretation,
we performed TUNEL assays to measure apoptotic cell
death in vitro. As shown in Fig. 3a, HETE treatment resulted
in 35–50% TUNEL-positive cells after 24 hours. Treatment
with 100 nmol/l AGN194204 alone did not produce signif-
icant increases in the number of apoptotic cells. However,
treatment with a combination of HETE and AGN194204
resulted in 50–75% TUNEL-positive cells after 24 hours.
This effect was more pronounced in SKBR3 and MDA-MB-
468 cells, which express higher levels of RXR-α protein.
These results indicate that selective PPAR activation can
produce different cellular responses in human breast can-
cer cell lines and that the RXR-selective ligand can poten-
tiate both antiproliferative and apoptotic effects.
To determine whether HETE-mediated apoptosis in human
breast cancer lines was the result of intrinsic or extrinsic
pathways, we examined patterns of caspase activation in
these cells. As shown in Fig. 3b, caspase 10 activation in
response to HETE (as shown by decreased immunoreactiv-
ity to the inactive proenzyme) was observed by 8 hours in
both T47D and MDA-MB-468 cells. Activation of the down-
stream effector caspase 3 was evident by 8–16 hours in
MDA-MB-468 cells. Caspase 9 expression was below the
detection limit for western blot in this cell line. Activation of
caspases 3 and 9 was not evident until 24 hours in T47D
cells, which correlated with slightly decreased numbers of
apoptotic cells at this time point. Activation of caspases in
the extrinsic (death receptor mediated) pathway such as
caspase 8 was not observed following HETE treatment
(data not shown). These results indicate that selective acti-
vation of PPAR-α activates the intrinsic apoptotic pathway
in human breast cancer cell lines.
RXR-α overexpression in human breast cancer cell lines 
results in phenotypic sensitization to the RXR-selective 
ligand
Our results suggest that RXR-α overexpression may sensi-
tize cells to the antiproliferative effects of AGN194204 and
potentiate additional PPAR-regulated responses in human
breast cancer cell lines. To test this hypothesis we overex-
pressed RXR-α by stable transfection in MCF7 and T47D
cells, which normally express low levels of the receptor.
RXR-α protein levels in these stable clones are shown in
Fig. 4a. To determine whether these clones were sensitized
to the antiproliferative effects of AGN194204, we per-
formed proliferation assays using ligand or vehicle treated
cells. As shown in Fig. 4b, treatment with 100 nmol/l
AGN194204 inhibited proliferation of RXR-αAvailable online http://breast-cancer-research.com/content/6/5/R546
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overexpressing T47D clones by 50%. Slightly greater inhi-
bition of proliferation (55%) by AGN194204 was observed
in RXR-α overexpressing MCF7 clones, reflecting higher
receptor expression in these cells (Fig. 4c). In contrast,
AGN194204 exposure had less effect on G418 resistant
control clones. AGN194204 also increased the percent-
age of apoptotic cells in cultures of RXR-α overexpressing
clones exposed to HETE. As shown in Fig. 4d,
AGN194204 increased the percentage of TUNEL-positive
cells by more than 50% in HETE-treated RXR-α overex-
pressing clones. In contrast, treatment with RXR-selective
ligand increased the percentage of TUNEL positive cells by
only 20% in HETE treated control clones. Treatment with
AGN194204 as a single agent had minimal effect on the
number of apoptotic cells in cultures of these clones. These
results indicate that RXR-α overexpression is sufficient to
Figure 3
The peroxisome proliferator-activated receptor (PPAR)-α-selective lig- and hydroxyeicosatetraenoic acid (HETE) induces apoptosis in human  breast cancer cell lines, which is potentiated by AGN194204 The peroxisome proliferator-activated receptor (PPAR)-α-selective lig-
and hydroxyeicosatetraenoic acid (HETE) induces apoptosis in human 
breast cancer cell lines, which is potentiated by AGN194204. (a) The 
indicated breast cancer cell lines were treated with vehicle (con), 100 
µmol/l HETE, 100 nmol/l AGN194204 (AGN), or both compounds 
simultaneously (HETE+AGN) for 24 hours. The percentage of apop-
totic cells was determined by dUTP nick-end labeling (TUNEL) assay 
and fluorescence microscopy. These experiments were performed 
three times, with similar results. Error bars indicate the standard error of 
the mean. (b) The PPAR-α-selective ligand HETE activates the intrinsic 
apoptotic pathway in human breast cancer cell lines. Whole cell lysates 
from the indicated breast cancer cell lines treated with 100 µmol/l 
HETE for up to 24 hours were subjected to western blot, with anti-cas-
pase (casp) and anti-β-actin antibodies shown on the left. Relative 
expression of each protein was determined using the same membrane. 
These experiments were performed three times, with similar results. 
Representative blots are shown.
Figure 4
Retinoid X receptor (RXR)-α overexpression induces ligand-selective  antiproliferative and apoptotic responses in human breast cancer cell  lines Retinoid X receptor (RXR)-α overexpression induces ligand-selective 
antiproliferative and apoptotic responses in human breast cancer cell 
lines. (a) RXR-α expression in T47D and MCF7 G418 resistant control 
clones (neo) and RXR-α stable clones (RXR-1, RXR-2). Whole cell 
lysates were subjected to western blot with anti-RXR-α and anti-β-actin 
antibodies. These experiments were repeated three times with inde-
pendent clones. Representative blots are shown. (b) RXR-α overex-
pression induces antiproliferative response to the RXR-selective ligand 
AGN194204 in T47D stable clones. Triplicate cultures of G418 resist-
ant control cells (neo) and RXR-α overexpressing clones (RXR1) were 
treated with vehicle or 100 nmol/l AGN194204 (AGN) for 6 days. Cells 
were counted at 2-day intervals using a hemacytometer. (c) RXR-α 
overexpression induces antiproliferative response to the RXR-selective 
ligand AGN194204 in MCF7 stable clones. Triplicate cultures of G418 
resistant control cells (neo) and RXR-α overexpressing clones (RXR1) 
were treated with vehicle or 100 nmol/l AGN194204 (AGN) for 6 days. 
Cells were counted at 2-day intervals using a hemacytometer. (d) RXR-
α overexpression potentiates the hydroxyeicosatetraenoic acid (HETE) 
apoptotic response to the RXR-selective ligand AGN194204 in T47D 
and MCF7 clones. G418 resistant control cells (neo) and RXR-α over-
expressing clones (RXR-1, RXR-2) were treated with vehicle (con), 100 
µmol/l HETE, 100 nmol/l AGN194204, or both compounds simultane-
ously (H+AGN) for 24 hours. The percentage of apoptotic cells was 
determined by dUTP nick-end labeling (TUNEL) assay using fluores-
cence microscopy. These experiments were performed three times, 
with similar results. Error bars indicate the standard error of the mean.Breast Cancer Research    Vol 6 No 5    Crowe and Chandraratna 
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sensitize breast cancer cell lines to the antiproliferative
effects of AGN194204 and potentiates the PPAR-α medi-
ated apoptotic response.
Discussion
One of the key findings of this study is that PPARs can
mediate selective responses in human breast cancer cell
lines, namely growth inhibition and apoptosis. Our data
indicate that PPAR-α, when activated by the selective lig-
and HETE, induces apoptosis in breast cancer cell lines.
This was characterized by activation of caspases 9 and 10
followed by caspase 3. Activation of caspase 8 was not
observed in cells treated with HETE. Future experiments
will characterize downstream targets of activated caspases
in HETE-treated cells. Conversely, LA-mediated activation
of PPAR-γ resulted in decreased growth characterized by
S-phase inhibition. PPAR-γ activation resulted in changes
in expression of a specific set of cell cycle regulatory
genes. Previous studies have indicated that PPAR-γ medi-
ates the action of LA in breast cancer cell lines [15]. These
cells have also been shown to contain a functional PPAR
response [14]. In addition to HETE and LA, studies have
shown that a variety of fatty acids can act as ligands for
PPARs, with disparate effects on promoter transactivation
[16]. This large group of natural ligands can complicate the
interpretation of studies examining the risk for breast can-
cer development associated with high-fat diets. The results
of our experiments suggest that PPAR ligands may affect
established breast cancer cell lines differently than normal
mammary epithelium in animal or human studies. In the rat
mammary carcinogenesis model, a synthetic PPAR-γ ligand
inhibited cancer development [18]. Clarification of these
effects awaits further experimentation.
Activation of PPAR-γ has been shown to have multiple anti-
tumor effects on breast cancer cells (for review, see Ker-
sten and coworkers [38]). PPAR-γ activation using
synthetic ligands such as TZDs was shown to induce lipid
accumulation in and differentiation of breast cancer cell
lines [17]. In the present study we did not observe these
types of changes; rather, PPAR-γ activation resulted in anti-
proliferative effects. These differences may be due to the
fact that different breast cancer cell lines were used in the
two studies. The role of PPAR-α ligands as a chemopre-
ventive or chemotherapeutic agent for breast cancer is less
clear. However, our studies indicate that PPAR-α activation
by HETE is a potent inducer of apoptosis in established
human breast cancer cell lines. In vitro studies are inher-
ently limited in determining the effects of PPAR activation
on clinical breast cancer, given that a phase II trial of trogl-
itazone showed little effect on refractory tumors [19].
Another important finding of the present study is the anti-
proliferative effect of the synthetic RXR ligand
AGN194204 on human breast cancer cell lines. Of
particular interest is the increased sensitivity to this ligand
of cell lines expressing higher levels of RXR-α. Some of
these estrogen receptor negative cell lines have been
shown to be resistant to the antiproliferative effects of the
RAR agonist all-trans RA [39]. The RXR ligand mediated
effects were associated with inhibition of growth factor sig-
naling and cell cycle regulatory pathways. RXR-α overex-
pression was sufficient to reproduce the effects of the
selective ligand in MCF7 and T47D cells. The effects of
AGN194204 on breast cancer cell lines suggest that this
ligand may have chemopreventive or chemotherapeutic
effects in vivo. In previous studies, synthetic RXR ligands
have been effective against mammary carcinogenesis in
animal models [33]. However, a phase II clinical trial of oral
bexarotene showed limited antitumor effects in patients
with metastatic breast cancer [36].
Our findings also demonstrate that AGN194204 potenti-
ated the antitumor effects of PPAR ligands. Combination of
PPAR and RXR ligands increased transactivation of a
responsive promoter in human breast cancer cell lines,
which is in agreement with previous studies [14]. These
results suggest that multidrug regimens consisting of
PPAR and RXR ligands may provide a therapeutic advan-
tage in breast cancer treatment. The molecular mecha-
nisms regulating these effects are currently unclear. PPAR
and RXR ligands have been shown to differentially recruit
subsets of transcriptional coactivator proteins to the recep-
tor complex [40]. Combinations of these ligands may result
in additional coactivator recruitment, leading to enhanced
transcriptional activation and cellular effects. The molecular
characterization of these pathways in human breast cancer
cells and testing the effects of PPAR and RXR ligands on
mammary carcinogenesis in coactivator-null mutant mice
will be important in future studies.
Conclusion
PPAR and RXR proteins are expressed by human breast
cancer cell lines. These proteins heterodimerize and trans-
activate a PPAR-responsive promoter. The magnitude of
transactivation was greater in breast cancer cell lines
expressing higher levels of RXR-α. PPAR-α and PPAR-γ
ligands induced apoptotic and antiproliferative responses
in these lines, respectively, which were associated with
specific changes in gene expression. These responses
were potentiated by the RXR-selective ligand
AGN194204. RXR-α overexpressing RA-resistant breast
cancer cell lines were more sensitive to the effects of the
RXR-selective compound. Forced RXR-α overexpression
in other breast cancer cell lines resulted in greater sensitiv-
ity to the selective ligand.
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